Date | Inventory | Goodwill | Total Assets | Current Liabilities |
---|
CEO | Dr. Jonathan Kaufman M.B.A., Ph.D. |
IPO Date | Dec. 19, 2022 |
Location | United States |
Headquarters | 7800 Susquehanna St. |
Employees | 5 |
Sector | Health Care |
Industries |
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Past 5 years
USD 24.98
USD 10.53
USD 5.56
USD 5.18
USD 20.46
USD 5.64
USD 1.60
USD 3.81
USD 12.74
StockViz Staff
January 15, 2025
Any question? Send us an email